Stanley Medical Research Institute

Back to Awarded Treatment Trials

Awarded Trial: 00-126

Grant ID

00-126

Illness

Schizophrenia

Primary Drug/Intervention

Rivastigmine

Primary Dosage

1.5 - 4.5 mg/bd

Secondary Drug Intervention

N/A

Secondary Dosage

N/A

Other Drug/Intervention

N/A

Other Dosage

N/A

Status

Completed

Investigator

Sharma

Sample Size

Duration of Study Period for Each Subject

12 weeks

Outcome Measurements

fMRI measurements during sustained attention task

Results

Twenty patients with rivastigmine treatment had more correct responses but the results did not achieve statistical significance. Treatment was also associated with increased activation of the cerebellum.

Publication

Aasen I et al. Effects of rivastigmine on sustained attention in schizophrenia; an fMRI study. J. Clin. Psychopharmacol. 2005;25:311-317.

Link

http://www.ncbi.nlm.nih.gov/pubmed/16012272

PI Name

Tonmoy Sharma

Degree

Center

Wellcome Senior Research Fellow in Basic Biomedical Science

Institution

Institute of Psychiatry

Address

PO78, De Crespigny Park

City or Town

London

State or Province

SE5 8AF

Zip or Postal Code